Clinical trial Recruiting at 1 site Interventional Ages 18 to 50 Women only

Comparing vaginal repair methods for cesarean section scar defects

Official title: Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect

Run by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · NCT05206682 · Data updated 2026-11-12

This study is testing if giving Leuprorelin injections to women after vaginal surgery for cesarean section scar defects can help them heal better by delaying their periods.

Quick facts

Study typeInterventional
Ages18 Years to 50 Years
SexWomen only
Enrollment94 (estimated)
SponsorXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedMay 1, 2023
Main results expectedApril 30, 2027
Study endsDecember 30, 2027
Registry record updatedApril 24, 2026
Trial IDNCT05206682 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women diagnosed with cesarean section scar defects complicated by adenomyosis and experiencing abnormal uterine bleeding.

Probably not a fit

Patients with malignant tumors, severe medical problems, or those who are pregnant will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of using Leuprorelin, a GnRH-a, to postpone menstruation after vaginal repair in women with cesarean section scar defects (CSD) complicated by adenomyosis. Participants will undergo vaginal excision and suture of the CSD, with one group receiving Leuprorelin injections while the other group will not. The study aims to assess whether delaying menstruation improves the healing prognosis of the scar over a six-month follow-up period.

Why it matters

Potential benefit: If successful, this approach could enhance healing outcomes for women suffering from cesarean section scar defects and adenomyosis.

How similar studies have gone: While the use of GnRH-a in similar contexts has shown promise, this specific approach is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Clearly diagnosed with CSD complicated with adenomyosis
2. Experiencing clinical features of abnormal uterine bleeding, prolonged menstrual flow (the duration of menstruation is more than 10 days).
3. The thickness of the remaining muscular layer of CSD was less than 3 mm.
4. Normal range of blood sugar and insulin
5. No serious medical problems (important viscera function in the normal range).
6. uterine fibroids no more than 5cm
7. Sign the informed consent.

Exclusion Criteria:

1. Indefinite diagnosis.
2. Malignant tumors.
3. With severe medical problems (severe liver disease, kidney disease, respiratory diseases, heart disease or uncontrolled diabetes, epilepsy, etc., dysfunction of important organs).
4. Pregnant.
5. Mental diseases.
6. Allergy to the any ingredients of Leuprorelin
7. Unwilling to comply with the research plan.

Where it's running

  • Shanghai Jiaotong University xinhua hospital
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.